Praxis Precision Medicines, Inc (PRAX) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $320.90: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 6.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Elevated put/call ratio: 2.29; Below-average business quality.
Praxis Precision Medicines is a clinical-stage CNS biopharma company developing small molecule and ASO therapies for neurological disorders via its Cerebrum and Solidus platforms. The company has filed NDAs with the FDA for ulixacaltmide (essential tremor) and relutrigine... Read more
Sell if holding. Engine safety override at $320.90: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 6.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Elevated put/call ratio: 2.29; Below-average business quality. Chart setup: RSI 52 mid-range, Bollinger mid-band. Score 5.2/10, moderate confidence.
Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and earnings proximity 0d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineulixacaltmide and relutrigine (NDA-filed)10-K Item 1A: 'we have submitted NDAs for ulixacaltmide for the treatment of ET and relutrigine for the treatment of SCN2A and SCN8A DEEs to the FDA'
Material Events(8-K, last 90d)
- 2026-02-10Item 5.02LOWAmendment to Jan 8, 2026 8-K: Board assigned Jeffrey Kindler to Audit and Nominating Committees, and Stuart Arbuckle to Compensation and Science and Technology Committees, effective February 6, 2026. Routine committee assignments for previously disclosed new directors.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
4 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Volatile — 6.2% daily ATR makes tight stops impractical. Position-size conservatively.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $320.90: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 6.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Elevated put/call ratio: 2.29; Below-average business quality. Chart setup: RSI 52 mid-range, Bollinger mid-band. Prior stop was $299.04. Score 5.2/10, moderate confidence.
Take-profit target: $570.81 (+77.5% upside). Prior stop was $299.04. Stop-loss: $299.04.
Concentration risk — Pipeline: ulixacaltmide and relutrigine (NDA-filed); Quality below floor (1.6 < 4.0); Value-trap signals (3/5): Revenue declining (-22.7% YoY), Margin compression (op margin -49.6%), Material insider selling (27 sells, 0.16% of cap).
Praxis Precision Medicines, Inc trades at a P/E of N/A (forward -37.6). TrendMatrix value score: 9.0/10. Verdict: Sell.
22 analysts cover PRAX with a consensus score of 4.1/5. Average price target: $634.
What does Praxis Precision Medicines, Inc do?Praxis Precision Medicines is a clinical-stage CNS biopharma company developing small molecule and ASO therapies for...
Praxis Precision Medicines is a clinical-stage CNS biopharma company developing small molecule and ASO therapies for neurological disorders via its Cerebrum and Solidus platforms. The company has filed NDAs with the FDA for ulixacaltmide (essential tremor) and relutrigine (SCN2A/SCN8A developmental and epileptic encephalopathy), with elsunersen and vormatrigine in earlier clinical stages; no products are commercially approved. Net losses were $303.3 million in 2025, with an accumulated deficit of $1.1 billion.